Can you teach me ssri…aa in everything, history, psychopharmacology,psychodynamics,kinetics, indications, guidelines, titration, switching, side effects, recent advances, contraindications, toxicity, discontinuation,dosage,formulation,evidence based trials,…and teach each drug individually too

Reading File

Finding Sources

Searching PubMed

"selective serotonin reuptake inhibitors"[MeSH Terms] AND "depression"[MeSH Terms]

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive data from multiple authoritative textbooks. Let me compile the complete, deeply detailed guide on SSRIs.

🧠 The Complete Guide to SSRIs (Selective Serotonin Reuptake Inhibitors)

PART 1 — HISTORY

Origins of the SSRI Era

The story of SSRIs begins not with psychiatry but with neuroscience. In the 1950s–60s, iproniazid (an MAO inhibitor, initially an anti-TB drug) and imipramine (the first TCA) were discovered serendipitously to relieve depression. The monoamine hypothesis of depression — that deficiency of serotonin and/or norepinephrine underlies depression — was proposed by Schildkraut (1965) and Bunney & Davis (1965).

In the 1960s, biochemist Arvid Carlsson (Nobel Prize, 2000) was studying selective neurotransmitter reuptake. His team at Astra in Sweden developed zimelidine — the first SSRI — in 1971. Zimelidine worked but was withdrawn in 1983 after cases of Guillain-Barré syndrome.

Fluoxetine (Prozac) was synthesized by Eli Lilly chemist Bryan Molloy and pharmacologist David Wong in 1972 and first approved by the FDA on December 29, 1987 — the most commercially and culturally transformative psychiatric drug in history. Its launch was chronicled by Peter Kramer in Listening to Prozac (1993), which placed SSRIs in mainstream culture.

The class then expanded:

Fluvoxamine — approved 1983 (Europe), 1994 (FDA for OCD)
Sertraline (Zoloft) — FDA approved 1991
Paroxetine (Paxil) — FDA approved 1992
Citalopram (Celexa) — FDA approved 1998
Escitalopram (Lexapro) — FDA approved 2002 (pure S-enantiomer of citalopram)

The impact was enormous: deaths from TCA overdose plummeted as SSRIs replaced them as first-line agents. By the 2000s, SSRIs were among the most prescribed drugs globally. — Kaplan & Sadock's Comprehensive Textbook of Psychiatry

PART 2 — PSYCHOPHARMACOLOGY & MECHANISM

The Serotonin System

Serotonin (5-hydroxytryptamine, 5-HT) is synthesized from tryptophan via tryptophan hydroxylase → 5-hydroxytryptophan → 5-HT. It is stored in vesicles in presynaptic neurons (mainly raphe nuclei in brainstem), released into the synapse, and normally recaptured via the serotonin transporter (SERT) on the presynaptic membrane.

SERT is a Na⁺/Cl⁻-dependent transporter encoded by the SLC6A4 gene. It pumps 5-HT back into the presynaptic neuron for repackaging or degradation by MAO-A.

Mechanism of SSRI Action

SSRIs bind to SERT with high affinity and selectivity, blocking the reuptake of serotonin from the synaptic cleft. This increases 5-HT concentration in the synapse and potentiates serotonergic neurotransmission. Their domain/mechanism in the Neuroscience-Based Nomenclature (NbN) system is:

Pharmacologic domain: Serotonin | Mechanism: Reuptake inhibitor (SERT) — Kaplan & Sadock

Why the Delay?

There is a therapeutic lag of 2–4 weeks before clinical antidepressant effects appear, despite immediate SERT blockade. The leading explanation:

Somatodendritic 5-HT1A autoreceptors on raphe neurons are initially stimulated by the increased synaptic 5-HT, causing a compensatory decrease in serotonin neuronal firing — attenuating the effect.
With sustained SSRI exposure, these autoreceptors desensitize/downregulate over 2–3 weeks, restoring normal firing rate but now with SERT blocked — producing net enhanced serotonin neurotransmission.
Downstream adaptive changes in postsynaptic receptor density, gene expression, neurotrophin signaling (BDNF upregulation), and neuroplasticity follow.

Why SSRIs ≠ More Effective Than TCAs — But Still First-Line

SSRIs have never been shown to be more effective than TCAs or MAOIs for depression. Their first-line status is entirely based on superior safety profile: far lower risk of anticholinergic effects, orthostatic hypotension, cardiotoxicity in overdose, and sedation. The wide therapeutic index was revolutionary — it became safe for PCPs to prescribe antidepressants. — Kaplan & Sadock

Psychodynamic Perspective

Psychodynamically, SSRIs alter the experiential landscape of mood disorders: patients often describe reduced affective lability, less reactivity to interpersonal slights, and improved mood stability. Some describe emotional blunting or "flattening" — an important side effect that can reduce engagement in psychotherapy. Early psychodynamic theorists viewed antidepressants as supplementary to exploratory therapy; current evidence strongly supports the combination of pharmacotherapy + psychotherapy as superior to either alone for moderate-to-severe depression.

PART 3 — PHARMACOKINETICS

The six core SSRIs differ importantly in their pharmacokinetic properties. Understanding these differences drives clinical decision-making.

Comparative Pharmacokinetics Table

Drug	Half-life	Active Metabolite	Protein Binding	CYP Metabolism	CYP Inhibition	Notable
Fluoxetine	1–4 days (fluoxetine) + 7–15 days (norfluoxetine)	Norfluoxetine (active)	~95%	CYP2D6	Strong 2D6, moderate 3A4	Longest t½, self-tapering
Sertraline	26 hrs	Desmethylsertraline (weakly active)	~98%	CYP2C9/2D6/3A4	Weak-moderate 2D6, mild 3A4	Best overall tolerability
Paroxetine	21 hrs (can vary greatly)	None (active parent)	~95%	CYP2D6	Strong 2D6 (self-inhibits)	Shortest t½ after fluoxetine withdrawn, highest discontinuation risk
Citalopram	35 hrs	Desmethylcitalopram (inactive)	~80%	CYP2C19, 3A4	Minimal CYP inhibition	Least drug-drug interactions
Escitalopram	27–32 hrs	S-desmethylescitalopram	~56%	CYP2C19, 3A4, 2D6	Minimal	Cleanest kinetics, most selective SERT
Fluvoxamine	15–20 hrs	None	~77%	CYP1A2	Strong 1A2, 3A4, 2C19	Most CYP interactions; approved OCD

Key points:

Fluoxetine's active metabolite norfluoxetine has a half-life of ~7–15 days, meaning steady state takes ~5 weeks and full washout takes 5–6 weeks. This is why fluoxetine must be stopped 5 weeks before an MAOI (vs. 2 weeks for other SSRIs).
Paroxetine is a strong CYP2D6 inhibitor and also inhibits its own metabolism at higher doses (nonlinear kinetics). It has the most anticholinergic activity of the class and the shortest effective half-life after steady state — highest risk of discontinuation syndrome.
Citalopram and escitalopram have minimal CYP interactions — the preferred choices in elderly patients on polypharmacy. — Harrison's 22E; Kaplan & Sadock

Absorption & Food Effects

All SSRIs are well absorbed orally. Food does not significantly affect absorption (sertraline is slightly better absorbed with food). All undergo first-pass hepatic metabolism.

Special Populations

Elderly: CYP metabolism slows → drug accumulation. Use lowest effective dose. Citalopram/escitalopram preferred.
Renal failure: Most SSRIs require no dose adjustment (hepatically metabolized). Monitor closely.
Hepatic failure: Reduce doses; clearance is impaired for all SSRIs.
Genetics (CYP2D6 polymorphisms): Poor metabolizers → higher paroxetine/fluoxetine levels. The SLC6A4 promoter "s" allele is associated with reduced SERT expression and a less robust SSRI response. — Kaplan & Sadock

PART 4 — INDICATIONS & APPROVED USES

SSRIs are approved across a remarkably wide range of disorders:

FDA-Approved Indications (by drug)

Indication	Fluoxetine	Sertraline	Paroxetine	Citalopram	Escitalopram	Fluvoxamine
Major Depressive Disorder	✅	✅	✅	✅	✅	❌
OCD	✅	✅	✅	❌	❌	✅
Panic Disorder	✅	✅	✅	❌	❌	❌
Social Anxiety Disorder	❌	✅	✅	❌	✅	✅
PTSD	❌	✅	✅	❌	❌	❌
GAD	❌	❌	✅	❌	✅	❌
PMDD	✅	✅	✅	❌	❌	❌
Bulimia Nervosa	✅	❌	❌	❌	❌	❌
Bipolar Depression (adj.)	✅	❌	❌	❌	❌	❌
Pediatric Depression	✅ (>8y)	❌	❌	❌	✅ (>12y)	❌

Off-Label (Evidence-Supported) Uses

Premature ejaculation (paroxetine, sertraline — strongest evidence; daily or on-demand)
Neuropathic pain (sertraline, fluoxetine — weaker evidence than SNRIs)
Hot flashes (paroxetine CR is FDA-approved — brand Brisdelle)
Irritable bowel syndrome (fluoxetine)
Post-stroke depression (sertraline, fluoxetine)
Body dysmorphic disorder (fluoxetine, escitalopram)
Autism spectrum disorder — behavioral symptoms (mixed evidence)
Chronic pain (SSRIs have analgesic properties; SNRIs generally superior) — Katzung 16E

PART 5 — CLINICAL GUIDELINES & TREATMENT PRINCIPLES

First-Line Status

All major guidelines (APA, NICE, BAP, WFSBP, Maudsley) designate SSRIs as first-line pharmacotherapy for MDD, GAD, SAD, OCD, and PTSD.

Acute Treatment

Goal: Full remission (not just response)
A meaningful trial is 6–8 weeks at therapeutic dose (not 2 weeks)
30–40% achieve remission with the first SSRI trial
If partial response: increase dose before switching
If no response at 4 weeks at therapeutic dose: switch or augment
70–80% ultimately achieve remission with sequential strategies (STAR*D data)

Continuation & Maintenance

After remission: continue for 6–9 months minimum to prevent relapse (not recurrence — relapse = same episode returning)
Recurrence prevention (maintenance): recommended if:
- ≥2 lifetime depressive episodes
- First episode was severe/suicidal/prolonged
- Age >50 (higher recurrence risk)
- Residual symptoms present
Landmark fluoxetine maintenance study: stopping at 12 weeks produced the highest relapse rate; stopping at 50 weeks had relapse rates no different from continued treatment — Maudsley Guidelines 15E
Duration of maintenance: at least 2 years, possibly indefinite after 3+ recurrences

Treatment-Resistant Depression (TRD)

Defined as failure of ≥2 adequate antidepressant trials. Options:

Augmentation: Add lithium, atypical antipsychotic (aripiprazole, quetiapine, brexpiprazole), mirtazapine, or bupropion
Switch: To SNRI, TCA, MAOI, or novel agent
Esketamine nasal spray (Spravato) — FDA-approved 2019 for TRD
ECT — most effective for TRD; gold standard

PART 6 — DOSAGE & TITRATION

Standard Dose Ranges

Drug	Starting Dose	Usual Therapeutic Dose	Maximum Dose
Fluoxetine	10–20 mg/day	20–60 mg/day	80 mg (OCD)
Sertraline	25–50 mg/day	50–200 mg/day	200 mg
Paroxetine (IR)	10–20 mg/day	20–60 mg/day	60 mg
Paroxetine CR	12.5–25 mg/day	25–62.5 mg/day	62.5 mg
Citalopram	10–20 mg/day	20–40 mg/day	40 mg (FDA cap due to QTc)
Escitalopram	5–10 mg/day	10–20 mg/day	20 mg
Fluvoxamine	50 mg/day	100–300 mg/day	300 mg

Source: Katzung 16E; Maudsley Guidelines 15E

Titration Principles

For SSRIs (unlike TCAs), the starting dose is usually a therapeutic dose — no obligatory titration required.
Exceptions: older adults, highly anxious patients, children → start at half the usual dose, increase after 2 weeks.
For elderly patients (Kaplan & Sadock): start paroxetine 10 mg, sertraline 25 mg, citalopram/escitalopram/fluoxetine 10 mg; titrate slowly.
Dose increases every 2–4 weeks if response is insufficient.
Allow 4–8 weeks at therapeutic dose before declaring failure.

OCD Dosing

OCD typically requires higher doses than depression:

Fluoxetine: up to 80 mg/day
Sertraline: up to 200 mg/day
Paroxetine: up to 60 mg/day
Response at anti-OCD doses takes longer (up to 12 weeks)

PART 7 — FORMULATIONS

Drug	Available Forms
Fluoxetine	Capsules (10/20/40 mg), tablets (10/20 mg), liquid (20 mg/5 mL), weekly delayed-release (90 mg — Prozac Weekly for maintenance)
Sertraline	Tablets (25/50/100 mg), oral concentrate (20 mg/mL)
Paroxetine	IR tablets (10/20/30/40 mg), CR tablets (12.5/25/37.5/62.5 mg; Paxil CR — fewer GI side effects), oral suspension (10 mg/5 mL)
Citalopram	Tablets (10/20/40 mg), oral solution (10 mg/5 mL)
Escitalopram	Tablets (5/10/20 mg), oral solution (5 mg/5 mL)
Fluvoxamine	Tablets (25/50/100 mg), CR capsules (100/150 mg)

Prozac Weekly (fluoxetine 90 mg): Enteric-coated pellets allowing once-weekly dosing for maintenance. Made possible by fluoxetine's exceptionally long half-life.

PART 8 — DRUG-DRUG INTERACTIONS (CYP450)

This is clinically critical.

Major Interaction Matrix

CYP Enzyme	Strongly Inhibited By	Major Substrates (↑ levels)
2D6	Fluoxetine, Paroxetine	TCAs, antipsychotics, β-blockers, type 1C antiarrhythmics (flecainide, propafenone), opioids (codeine→morphine), tamoxifen
1A2	Fluvoxamine	Theophylline, clozapine, haloperidol, warfarin
3A4	Fluvoxamine, fluoxetine (mod.)	Benzodiazepines (alprazolam, triazolam), carbamazepine, digoxin, statins, many antiretrovirals
2C19	Fluvoxamine, fluoxetine (mod.)	Omeprazole, phenytoin, some TCAs

Critical interaction — Tamoxifen: Fluoxetine and paroxetine (strong CYP2D6 inhibitors) block conversion of tamoxifen to its active metabolite endoxifen → renders tamoxifen ineffective in breast cancer. Use citalopram or escitalopram instead.

Citalopram and Escitalopram: Minimal CYP interactions → preferred in polypharmacy. — Harrison's 22E; Kaplan & Sadock

Serotonin Syndrome Risk

Combining SSRIs with other serotonergic agents can trigger serotonin syndrome. High-risk combinations:

SSRI + MAOI (absolute contraindication — can be fatal)
SSRI + linezolid or methylene blue (MAO-inhibiting antibiotics)
SSRI + tramadol or fentanyl
SSRI + triptans (theoretical, low absolute risk)
SSRI + lithium (augments serotonin; monitor)
SSRI + dextromethorphan

Washout before starting MAOI: 2 weeks for most SSRIs; 5 weeks for fluoxetine (due to norfluoxetine).

PART 9 — SIDE EFFECTS

Gastrointestinal

Nausea, diarrhea, loose stools — most common, especially early; related to gut 5-HT3/4 stimulation
Usually transient (2–4 weeks)
Taking with food reduces nausea
Sertraline concentrate must be diluted — causes mucosal irritation if undiluted

Sexual Dysfunction

Most underreported and persistent side effect — affects 30–70% of patients
Reduced libido, anorgasmia, delayed ejaculation, erectile dysfunction
Caused by 5-HT2 receptor-mediated suppression of dopaminergic pathways
Paroxetine and fluoxetine highest risk; citalopram/escitalopram somewhat lower
Management options:
- Drug holiday (taking one missed dose before anticipated sexual activity — works for short-acting SSRIs except fluoxetine)
- Dose reduction
- Switch to bupropion (lowest sexual side effects) or mirtazapine
- Add sildenafil (for erectile dysfunction in men)
- Add bupropion as augmentation
- Switch to vortioxetine (emerging evidence of better sexual side effect profile) — Maudsley Guidelines 15E

Weight Effects

Paroxetine: most weight gain (antihistaminergic and anticholinergic properties)
Fluoxetine: mild initial weight loss, may gain with long-term use
Sertraline/escitalopram: modest long-term weight gain
Fluvoxamine: moderate weight gain

CNS Effects

Insomnia/activation: especially fluoxetine — dose in morning
Sedation: fluvoxamine > paroxetine (take at bedtime)
Headache: common at initiation
Emotional blunting: described as "not caring" — affects up to 40%; may require dose reduction or switch
Akathisia: inner restlessness, increased motor activity — especially early in treatment; can be mistaken for anxiety worsening

Serotonin Syndrome (Overdose/Drug Interaction)

Classic triad:

Neuromuscular excitability — tremor, clonus, hyperreflexia, myoclonus
Autonomic instability — tachycardia, hyperthermia, diaphoresis, labile BP
Altered mental status — agitation, confusion

Hunter Criteria differentiate from NMS (which is slower onset, bradykinesia-dominant, no clonus). SSRIs alone at therapeutic doses rarely cause serotonin syndrome; the risk rises dramatically with polypharmacy. — Harrison's 22E

Cardiovascular

SSRIs generally safe cardiovascularly
Citalopram and escitalopram can prolong QTc at higher doses → FDA cap: citalopram ≤40 mg/day (≤20 mg in elderly, hepatic impairment, or CYP2C19 inhibitor use)
SSRIs may modestly decrease heart rate
Generally safe in post-MI depression (SADHART trial — sertraline)

Bleeding

SSRIs inhibit SERT on platelets → deplete platelet serotonin → impaired platelet aggregation → increased bleeding risk
Risk of upper GI bleeding (HR ~1.97) and lower GI bleeding (HR ~2.96)
Risk highest in first 30 days of treatment
Strongest inhibitors of platelet 5-HT: sertraline, paroxetine, fluoxetine
Co-prescribing NSAIDs or anticoagulants multiplies this risk substantially
Consider PPI prophylaxis when co-prescribing with NSAIDs, antiplatelet drugs, or anticoagulants — Maudsley Guidelines 15E

Hyponatremia (SIADH)

SSRIs can cause SIADH — particularly in elderly
Mechanism: enhanced 5-HT-mediated stimulation of ADH release
Risk factors: age >65, female sex, low BMI, diuretic use
Monitor Na⁺ in first weeks in high-risk patients
Paroxetine and fluoxetine carry the highest risk; escitalopram somewhat lower

Bone

Chronic SSRI use associated with reduced bone density and increased fracture risk — mechanism includes serotonergic inhibition of osteoblast differentiation

Suicidality (Black Box Warning)

FDA Black Box Warning: SSRIs may increase suicidal ideation and behavior in children, adolescents, and young adults (≤24 years) in the first weeks of treatment
Mechanism unclear — may relate to activation/akathisia
The benefit/risk ratio still favors treatment in most patients
Monitor closely in first 1–4 weeks, especially in young patients

PART 10 — CONTRAINDICATIONS

Absolute Contraindications

Concurrent MAOI use — risk of life-threatening serotonin syndrome
- Exception: wait ≥14 days after MAOI discontinuation before starting SSRI (≥5 weeks after stopping fluoxetine; ≥2 weeks after stopping SSRI before starting MAOI)
Pimozide with fluvoxamine — CYP1A2 inhibition → pimozide toxicity
Thioridazine — QTc prolongation
Linezolid / IV methylene blue — MAO-inhibiting drugs → serotonin syndrome

Relative Contraindications / Cautions

Bipolar disorder (unprotected by mood stabilizer) — risk of precipitating mania or rapid cycling; always co-prescribe a mood stabilizer
Epilepsy — SSRIs may lower seizure threshold (modest)
Bleeding disorders / concurrent anticoagulants / NSAIDs — monitor carefully, consider PPI
Severe hepatic impairment — reduce dose
QTc prolongation or cardiac arrhythmias — avoid high-dose citalopram
Pregnancy — see below
Tamoxifen use — avoid fluoxetine and paroxetine; use citalopram/escitalopram

Pregnancy & Lactation

First trimester exposure: Small increase in cardiac septal defects with paroxetine (risk ~1.5–2%; background risk ~1%) — paroxetine Category D historically, now avoid in pregnancy if possible
Third trimester: Neonatal adaptation syndrome — jitteriness, respiratory distress, poor feeding, transient
Persistent pulmonary hypertension of the newborn (PPHN): Associated with SSRI exposure after 20 weeks (absolute risk small: ~3/1000 vs ~1–2/1000 background)
Benefits vs. risks: Untreated maternal depression is also harmful. Sertraline and escitalopram are preferred in pregnancy — minimal drug-drug interactions, reasonable safety data
Breastfeeding: Sertraline and paroxetine have lowest infant serum levels; generally safe. Fluoxetine has higher transfer and longer half-life — more caution needed
A 2025 umbrella review (PMID: 39266712) confirmed most SSRIs are generally acceptable in pregnancy with appropriate monitoring — Mol Psychiatry 2025

PART 11 — SWITCHING ANTIDEPRESSANTS

Switching is complex and requires attention to pharmacokinetics and pharmacodynamics.

General Principles (Maudsley Guidelines 15E)

Avoid abrupt withdrawal of the first drug (unless serious adverse event)
Cross-tapering is preferred: slowly reduce the first drug while slowly introducing the second
Speed of cross-taper guided by patient tolerability — may need hyperbolic tapering
SSRI to SSRI: May not always need cross-taper — the new SSRI can ameliorate withdrawal of the first. But stopping paroxetine abruptly and starting fluoxetine → virtual 80% reduction in drug activity (fluoxetine takes 1–2 weeks to reach steady state) → withdrawal very likely
Short treatment (<3–4 weeks): Can stop abruptly and start next day

Switching Table (Maudsley 15E)

From → To	Strategy
Any SSRI → Another SSRI	Cross-taper preferred; reduce first to minimum effective dose before switch
SSRI → SNRI	Cross-taper
SSRI → Mirtazapine	Cross-taper (example: reduce citalopram over 4 weeks while introducing mirtazapine)
SSRI → TCA	Cross-taper carefully (additive serotonin and cardiac effects possible)
SSRI → MAOI	Must wash out SSRI first: 2 weeks (most SSRIs), 5 weeks (fluoxetine)
MAOI → SSRI	Must wait 2 weeks after stopping MAOI
Paroxetine/Fluoxetine → Tamoxifen-compatible agent	Switch to sertraline, citalopram, or escitalopram

PART 12 — DISCONTINUATION SYNDROME

Overview

When SSRIs are stopped abruptly or rapidly tapered, a discontinuation (withdrawal) syndrome can occur. This is not addiction — but a physiological adaptation.

Symptoms (FINISH Mnemonic)

Flu-like symptoms (myalgia, sweating, chills)
Insomnia (vivid dreams, nightmares)
Nausea
Imbalance (dizziness, ataxia, "brain zaps" — electric shock sensations)
Sensory disturbances (paresthesias, "brain zaps")
Hyperarousal (irritability, anxiety, agitation)

Risk by Drug

Highest risk: Paroxetine (short half-life + strong SERT binding + anticholinergic rebound)
Moderate: Sertraline, fluvoxamine, citalopram, escitalopram
Lowest risk: Fluoxetine (long half-life = self-tapering)

Severity

Can range from mild/brief (days) to prolonged withdrawal lasting months or years in a minority of patients — this phenomenon is increasingly recognized and was largely missed in original clinical trials.

Management

Prevention: Never stop abruptly; taper over weeks to months
Hyperbolic tapering: At lower doses, each dose reduction produces larger proportional receptor change → need smaller absolute dose reductions at low doses (e.g., use liquid formulations)
Fluoxetine bridge: Switch to fluoxetine → its long half-life causes self-tapering → facilitates discontinuation
Symptoms appearing despite taper: Slow the taper; consider longer maintenance — Maudsley Deprescribing Guidelines; Maudsley 15E

PART 13 — TOXICITY & OVERDOSE

SSRI Overdose Alone

Generally much safer than TCAs or MAOIs
Fatalities from SSRI overdose alone are extremely uncommon
Symptoms: nausea, vomiting, tremor, agitation, drowsiness, QTc prolongation at high doses
Citalopram in particular can cause seizures and QTc prolongation in overdose (even at doses of 600 mg+)
Management: Supportive care, cardiac monitoring, activated charcoal if within 1 hour

Serotonin Syndrome (Severe Toxicity)

The life-threatening form (when SSRIs are combined with other serotonergic agents):

Triad: Hyperthermia, neuromuscular abnormalities (clonus, hyperreflexia, myoclonus), altered consciousness
Temperature ≥41°C → medical emergency
Management:
1. Stop all serotonergic agents immediately
2. Benzodiazepines for agitation/seizures
3. Cyproheptadine (5-HT2A antagonist) — 12 mg loading dose, then 2 mg every 2 hours if symptoms continue
4. Aggressive cooling, ICU monitoring, intubation if severe
5. Avoid antipyretics (not effective — hyperthermia is from muscle activity)

Fatal overdoses with SSRIs usually involve polysubstance ingestion (SSRIs + alcohol, benzodiazepines, or other CNS depressants). — Katzung 16E

PART 14 — EVIDENCE-BASED TRIALS

Landmark Studies

STAR*D (Sequenced Treatment Alternatives to Relieve Depression) — Rush et al., 2006

4,000+ patients, real-world MDD
Level 1: Citalopram → 28% remission (QIDS-SR)
Level 2: Switch or augment → ~30% additional remission
Level 3: MAOI or augmentation → ~14% more
Teaching point: sequential treatment achieves remission in ~70% but takes multiple trials

SADHART — Glassman et al., JAMA 2002

Sertraline in post-MI depression — safe and effective; no adverse cardiac outcomes vs. placebo
Established SSRI safety in cardiovascular disease

CISR-A Trial (NICE, UK)

Established SSRIs vs. CBT and combination — combination superior for moderate-severe depression

Cipriani et al., Lancet 2018 (meta-analysis of 522 RCTs, 116,000 patients)

All 21 antidepressants were more effective than placebo
Escitalopram and sertraline had the best efficacy-acceptability balance
First comprehensive head-to-head comparison; largely validated current first-line choices

ADAPT Trial (2010)

Added antidepressant to SSRI vs. switch: augmentation and switching equally effective
Supports the flexibility of treatment decisions

PREVENT Study (Geddes et al., 2003 — landmark maintenance meta-analysis)

Antidepressant maintenance for 1 year reduced recurrence risk by 70% vs. placebo

PMDD Studies: Fluoxetine (Eli Lilly PREMENSTRUAL DYSPHORIC DISORDER study) and sertraline (Yonkers et al.) — both approved for PMDD, with luteal-phase dosing as effective as continuous dosing in some studies. — Katzung 16E; Kaplan & Sadock

PART 15 — EACH SSRI INDIVIDUALLY

🔷 1. FLUOXETINE (Prozac)

History: First SSRI synthesized (1972), FDA-approved 1987. Defined the SSRI era. Brand "Prozac" became culturally synonymous with antidepressants.

Mechanism: SERT inhibitor; mild 5-HT2C antagonism may contribute to activating effects and less weight gain. Weak inhibitor of NET.

Kinetics:

Half-life: ~1–4 days (fluoxetine) + 7–15 days (norfluoxetine)
Active metabolite norfluoxetine is equally potent at SERT
Steady state: ~5 weeks
Washout: 5–6 weeks
CYP2D6 metabolism; strong 2D6 inhibitor
Protein binding: ~95%

Dose: 10–20 mg/day start; 20–60 mg/day therapeutic; up to 80 mg for OCD Formulations: Capsules, tablets, liquid, Prozac Weekly (90 mg)

Indications: MDD, OCD, panic disorder, bulimia nervosa, PMDD, pediatric depression (≥8 years), bipolar depression (with olanzapine — Symbyax)

Unique features:

Most activating SSRI — dose in the morning
Least weight gain long-term
Self-tapering due to long t½ → lowest discontinuation risk
5 week washout before MAOI (vs. 2 weeks for others)
Inhibits tamoxifen activation (avoid in breast cancer patients)
May precipitate akathisia early in treatment

Side effects: Insomnia, activation, sexual dysfunction, mild initial weight loss → possible long-term gain, headache

Evidence: STAR*D Level 1; Cipriani 2018 (good efficacy); landmark pediatric depression trials (TADS trial — fluoxetine + CBT superior)

🔷 2. SERTRALINE (Zoloft)

History: FDA approved 1991. Became one of the most prescribed drugs in the US by the 2000s.

Mechanism: Most selective SERT inhibitor of the group. Weak DAT (dopamine transporter) inhibitor at high doses — possible mild dopaminergic contribution.

Kinetics:

Half-life: ~26 hours (linear kinetics)
Active metabolite: Desmethylsertraline (very weak — clinically insignificant)
CYP2C9/2D6/3A4 metabolism; mild–moderate CYP inhibition
Protein binding: ~98%

Dose: 25–50 mg/day start; 50–200 mg/day; take with food to improve absorption

Formulations: Tablets (25/50/100 mg), oral concentrate (20 mg/mL — must be diluted)

Indications: MDD, OCD, panic disorder, SAD, PTSD, PMDD, pediatric OCD

Unique features:

Best overall tolerability profile (Cipriani 2018)
Most versatile — most FDA approvals in the class
Preferred in cardiovascular disease (SADHART), pregnancy, post-MI depression
Moderate discontinuation risk
Lowest sexual side effects among commonly used SSRIs (except escitalopram)
Oral concentrate must be diluted in water, orange juice, or lemonade (not carbonated drinks)

Side effects: GI symptoms (most common early), sexual dysfunction (moderate), mild weight gain

Evidence: SADHART (post-MI), PTSD trials, PMDD trials; among top performers in Cipriani 2018 meta-analysis for acceptability

🔷 3. PAROXETINE (Paxil / Paxil CR / Seroxat)

History: FDA approved 1992. Most anticholinergic SSRI. Highest discontinuation syndrome risk.

Mechanism: SERT inhibitor; also inhibits norepinephrine transporter (NET) — contributes to anxiolytic effect. Inhibits muscarinic receptors (anticholinergic). Inhibits nitric oxide synthase (contributes to sexual dysfunction). At higher doses: sigma-1 receptor activity.

Kinetics:

Half-life: ~21 hours (BUT paroxetine inhibits its own CYP2D6 metabolism → nonlinear pharmacokinetics; at steady state, small dose increases → large plasma level increases)
No active metabolite
Strong CYP2D6 inhibitor (second only to some TCAs)
Protein binding: ~95%
Highest anticholinergic activity of any SSRI

Dose:

IR: 10–20 mg start; 20–60 mg therapeutic
CR: 12.5–25 mg start; 25–62.5 mg therapeutic
GAD, PTSD, panic: 20–50 mg usual

Formulations: IR tablets, CR tablets, oral suspension

Indications: MDD, OCD, GAD, SAD, panic disorder, PTSD, PMDD

Unique features:

Most sedating SSRI → give at bedtime
Most weight gain in the class (antihistaminergic + anticholinergic)
Highest sexual dysfunction rate (NOS inhibition)
Avoid in pregnancy (cardiac septal defects — Paroxetine Pregnancy Registry data)
Highest discontinuation syndrome risk — never stop abruptly; use liquid for fine-taper
Blocks CYP2D6 → inhibits tamoxifen → contraindicated in breast cancer on tamoxifen
CR formulation reduces GI side effects
Brisdelle (paroxetine 7.5 mg CR) — FDA-approved for menopausal hot flashes

Side effects: Sedation, weight gain, sexual dysfunction (highest), constipation, dry mouth (anticholinergic), cognitive blunting

🔷 4. CITALOPRAM (Celexa)

History: Developed by Lundbeck (Denmark), FDA approved 1998. Racemic mixture of R- and S-enantiomers.

Mechanism: SERT inhibitor. The R-enantiomer may have weak antagonism at histamine H1 receptors and may slightly attenuate the therapeutic effects of the S-enantiomer. Least CYP interactions of the first 5 SSRIs.

Kinetics:

Half-life: ~35 hours (longest among SSRIs after fluoxetine)
Active metabolites: Desmethylcitalopram, didesmethylcitalopram — not clinically significant
CYP2C19 and 3A4 metabolism
Minimal CYP inhibition
Protein binding: ~80% (lowest of class)

Dose: 10–20 mg start; 20–40 mg/day usual; FDA maximum: 40 mg/day (QTc risk at higher doses)

In elderly, hepatic impairment, or on CYP2C19 inhibitors (e.g., omeprazole): maximum 20 mg/day

Formulations: Tablets, oral solution

QTc Warning: Citalopram dose-dependently prolongs QTc; FDA issued safety communication in 2011. Doses >40 mg no longer recommended. This limits its utility in refractory cases.

Indications: MDD (only FDA indication), widely used off-label for anxiety

Unique features:

Fewest drug-drug interactions → excellent choice for medically complex patients
Preferred in elderly on polypharmacy (alongside escitalopram)
QTc concern at higher doses — monitor ECG
Moderate discontinuation risk

Side effects: GI (dose-related), sexual dysfunction (moderate), drowsiness (mild), QTc prolongation

🔷 5. ESCITALOPRAM (Lexapro / Cipralex)

History: Developed as the pure S-enantiomer of citalopram by Lundbeck; FDA approved 2002. Twice as potent as citalopram at SERT with fewer off-target effects.

Mechanism: Most selective SSRI — highest SERT affinity and selectivity of the class. No significant affinity for histaminergic, dopaminergic, muscarinic, or adrenergic receptors. The R-enantiomer (in citalopram) slightly inhibits SERT binding — removing it (escitalopram) results in a cleaner, more potent drug.

Kinetics:

Half-life: ~27–32 hours
Linear pharmacokinetics
CYP2C19, 3A4, 2D6 (minor)
Minimal CYP inhibition
Protein binding: ~56% (lowest of class)

Dose: 5–10 mg start; 10–20 mg therapeutic; maximum 20 mg/day

Elderly/hepatic impairment: maximum 10 mg/day

Formulations: Tablets, oral solution

Indications: MDD, GAD (both adults and adolescents ≥12 years), pediatric MDD

Unique features:

Best efficacy-tolerability balance in Cipriani et al. 2018 meta-analysis (522 RCTs)
Most selective SERT binding → fewest off-target side effects
Preferred in elderly, pregnancy, breastfeeding, polypharmacy
Minimal drug interactions
Less likely to cause drug interactions than citalopram despite higher potency
Moderate discontinuation risk (shorter t½ than fluoxetine)
QTc — also mild prolongation but less than citalopram at equivalent doses

Side effects: Generally best-tolerated; GI effects, mild sexual dysfunction, insomnia or somnolence

Evidence: Multiple head-to-head trials vs. SSRIs and SNRIs; duloxetine vs. escitalopram studies showed comparable efficacy with better tolerability for escitalopram. Widely considered empirically "best in class" by contemporary guidelines.

🔷 6. FLUVOXAMINE (Luvox / Faverin)

History: First SSRI approved in Europe (1983); FDA approved 1994 for OCD. Not approved for MDD in the US but widely used off-label and approved for depression elsewhere.

Mechanism: SERT inhibitor; also a sigma-1 receptor agonist — may contribute to anxiolytic and neuroprotective effects (possibly relevant to long COVID/SARS-CoV-2 neuropsychiatric effects — emerging research 2020–2022).

Kinetics:

Half-life: 15–22 hours (shorter)
No active metabolites
CYP1A2 substrate
Most CYP interactions of any SSRI: strong 1A2, 2C19, 3A4 inhibitor
Protein binding: ~77%

Dose: 50 mg/day start; 100–300 mg/day therapeutic; doses >150 mg split BID Formulations: Tablets (25/50/100 mg), CR capsules (100/150 mg)

Indications: OCD (adults and children), SAD (off-label MDD)

Unique features:

Most drug interactions in the class → must review all co-medications
- Fluvoxamine + clozapine → clozapine toxicity (CYP1A2 inhibition)
- Fluvoxamine + theophylline → toxicity
- Fluvoxamine + warfarin → ↑ anticoagulation
- Fluvoxamine + caffeine → ↑ caffeine levels
More sedating → give at bedtime
Sigma-1 receptor agonism: explored for COVID-19 (TOGETHER trial — fluvoxamine reduced hospitalization), Long COVID depression
Moderate GI side effects
Most used for OCD; not widely used for depression in US

Side effects: Nausea (highest in class), sedation, weight gain (moderate), significant drug interactions

PART 16 — RECENT ADVANCES (2022–2026)

Fluvoxamine and COVID-19: The TOGETHER trial (Reis et al., LANCET Global Health 2022) showed fluvoxamine reduced the risk of hospitalization in COVID-19 outpatients. Mechanism: sigma-1 receptor agonism → reduced inflammatory cytokine storm. A major non-psychiatric application.
Escitalopram as "best in class": Cipriani et al. (Lancet 2018) and subsequent analyses continue to support escitalopram for optimal efficacy-tolerability; confirmed in real-world effectiveness studies.
SSRI + psychotherapy evidence: Growing meta-analytic data confirm that combined CBT + SSRI is superior to either monotherapy for moderate-to-severe MDD, anxiety disorders, and OCD.
Post-SSRI Sexual Dysfunction (PSSD): Recognized as a distinct syndrome where sexual dysfunction persists after SSRI discontinuation, sometimes indefinitely. Under investigation; estimated prevalence 0.5–3% of SSRI users. FDA updated labeling in 2019. Mechanism may involve epigenetic changes in serotonin receptor expression. — Maudsley Guidelines 15E; Tarchi et al. 2023 systematic review
Hyponatremia network meta-analysis (PMID: 40261584, 2025): Paroxetine and escitalopram associated with highest hyponatremia risk among antidepressants; citalopram intermediate.
Pharmacogenomics-guided prescribing: FDA has approved GeneSight and similar tests for CYP2D6/2C19 genotyping to guide SSRI selection. Evidence for clinical utility is still debated; 2021 PRIME Care RCT showed modest benefits.
Vortioxetine and vilazodone — often called "SSRIs+" (SERT inhibitors + 5-HT1A agonism), considered separately from classical SSRIs but represent the evolution of the class with potential cognitive and sexual side effect advantages.
SSRI in Parkinson's disease depression: 2024 systematic review and meta-analysis (PMID: 38960993) confirmed SSRI efficacy for depression in Parkinson's, with careful monitoring for worsening motor symptoms needed.
Drug holidays for sexual dysfunction: 2024 RCTs (PMID: 25162448 concept, updated 2024 trials in Maudsley) confirmed drug holidays (one missed dose) are effective for short-acting SSRIs — paroxetine, sertraline — but not fluoxetine due to long half-life.

PART 17 — QUICK REFERENCE COMPARISON SUMMARY

Feature	Fluoxetine	Sertraline	Paroxetine	Citalopram	Escitalopram	Fluvoxamine
t½	~7d (norfluox)	26h	21h	35h	27–32h	15–22h
CYP inhibition	Strong 2D6	Mild	Strong 2D6	Minimal	Minimal	Strong 1A2/3A4/2C19
Weight gain	Least	Mild	Most	Moderate	Mild	Moderate
Sexual SE	High	Low-moderate	Highest	Moderate	Low-moderate	Moderate
Sedation	Low (activating)	Low-moderate	High	Low-moderate	Low	High
Discontinuation risk	Lowest	Moderate	Highest	Moderate	Moderate	Moderate
Drug interactions	Significant	Low	Significant	Minimal	Minimal	Most
Pregnancy preference	Caution	✅ Preferred	❌ Avoid	Moderate	✅ Preferred	Caution
Elderly preference	Moderate	Good	❌ Avoid	✅ Preferred	✅ Preferred	Avoid
Best for	Bulimia, PMDD, pediatric depression	Most indications, CVD, pregnancy	Anxiety disorders, GAD, PTSD	Elderly, polypharmacy	First-line; best tolerated	OCD
Avoid with	MAOIs, tamoxifen	MAOIs	MAOIs, tamoxifen, pregnancy	MAOIs, high dose	MAOIs	MAOIs, clozapine, theophylline

Sources

Kaplan & Sadock's Comprehensive Textbook of Psychiatry — Chapter 33.5a (Serotonin Reuptake Inhibitors)
Harrison's Principles of Internal Medicine 22E (2025) — Chapter on Depressive Disorders
Katzung's Basic and Clinical Pharmacology, 16th Edition — Chapter 30 (Antidepressants)
The Maudsley Prescribing Guidelines in Psychiatry, 15th Edition — Sections on switching, discontinuation, SSRIs and bleeding, prophylaxis
The Maudsley Deprescribing Guidelines — SSRI/SNRI tapering and discontinuation
Adams and Victor's Principles of Neurology, 12th Edition
Cipriani et al. PMID 29477251 — Lancet 2018 (522 RCTs, 116,000 patients)
PMID 39266712 — Safety of psychotropic medications in pregnancy (Mol Psychiatry 2025)
PMID 38960993 — SSRIs in Parkinson's depression (Clin Drug Investig 2024)
PMID 40261584 — Antidepressants and hyponatremia network meta-analysis (J Endocrinol Invest 2025)

This guide covers every dimension of SSRI pharmacology and clinical use from history through 2026 evidence. If you want me to go deeper on any individual drug, specific indication (e.g., OCD titration protocols, pediatric use, pregnancy management), augmentation strategies, or a particular clinical scenario — just ask.

This is a shared conversation. Sign in to Orris to start your own chat.